News Pharma Mar, S.A.

Equities

PHM

ES0169501022

Market Closed - BME Other stock markets 11:35:28 2024-04-18 am EDT			5-day change	1st Jan Change
26.62 ^EUR	+0.38%		-3.83%	-35.20%

Feb. 29	Transcript : Pharma Mar, S.A., 2023 Earnings Call, Feb 29, 2024
Feb. 28	Pharma Mar, S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Transcript : Pharma Mar, S.A., 2023 Earnings Call, Feb 29, 2024	Feb. 29
Pharma Mar, S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 27	CI
PharmaMar presents new results of lurbinectedin at the ASCO Symposium on Genitourinary Cancers	Jan. 30	AQ
Pharma Mar's Sylentis Meets Primary Endpoint for Dry Eye Disease Medication	Dec. 18	MT
Pharma Mar Partner Wins Marketing Approval for Lung Cancer Drug in Hong Kong	Dec. 12	MT
PharmaMar receives approval of Zepzelca for the treatment of metastatic small cell lung cancer in Macau, China	Dec. 05	AQ
Pharma Mar Partner Wins Approval for Lung Cancer Drug in Macao	Dec. 04	MT
Pharma Mar's Partner Wins Commercialization Approval for Zepzelca in Peru	Nov. 07	MT
PharmaMar receives a payment of 10 million dollars from Janssen as a commercial milestone	Nov. 07	AQ
PharmaMar Gets $10 Million Milestone Payment from Janssen Under Yondelis Licensing Deal	Nov. 06	MT
Transcript : Pharma Mar, S.A., Q3 2023 Earnings Call, Oct 27, 2023	23-10-27
Pharma Mar, S.A. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-25	CI
PharmaMar presents new data on lurbinectedin for small cell lung cancer at ESMO 2023	23-10-19	AQ
PharmaMar increased investment in R&D in oncology by 23% in 2022	23-09-25	AQ
PharmaMar licenses lurbinectedin to Key Oncologics for marketing and distribution in Africa	23-09-13	AQ
PharmaMar will present new data on lurbinectedin at the IASLC 2023 World Lung Cancer Congress	23-09-11	AQ
Pharma Mar, S.A. commences an Equity Buyback Plan, under the authorization approved on May 31, 2023.	23-09-05	CI
Transcript : Pharma Mar, S.A., H1 2023 Earnings Call, Jul 28, 2023	23-07-28
Pharma Mar, S.A. Reports Earnings Results for the Half Year Ended June 30, 2023	23-07-27	CI
PharmaMar receives approval of Zepzelca for the treatment of metastatic small cell lung cancer in Oman	23-07-20	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Pharma Mar, S.A.

Equities

PHM

ES0169501022

Summary

Filters